The Regenerative Medicine Catalyst Body
Australia has a strong and active Regenerative Medicine (RM) industry eco-system with internationally-recognised basic and translational research, clinical trials framework and clinical centres, with more than 30 companies in Australia developing products and more than 30 clinical trials in progress.
This project will build on the Regenerative Medicine Advisory Group report, 'Regenerative medicine: Opportunities for Australia' (MTPConnect, LEK, 2018) and investigate and analyse the Regenerative medicine sector in all four Industry Growth Centre (IGC) pillars:
- Increasing collaboration and commercialisation across the sector
- Improving management and workforce skills
- Improving access to global supply chains and international markets
- Optimising the regulatory environment
These details will be presented by September 2021.
Outcomes: The key challenges of the sector lie in workforce capabilities, collaboration, funding, regulation and policy infrastructure and Australian manufacturing capability. Work is well underway with a number of reports and white papers investigating solutions to these challenges and benchmarking the current landscape.
|Consortium Members||Medicines Australia, Cell Therapies, BioIntelect, Novartis Pharmaceuticals & Research Strategies Australia|
|Project Duration||September 2020 - September 2021 (Finished)|
|Contact||Lorraine Chiroiu - CEO AusBiotech - email@example.com|
Visit AusBiotech for more information | Twitter: @AusBiotech | LinkedIn: AusBiotech